Zobrazeno 1 - 10
of 786
pro vyhledávání: ''
Autor:
Eric S Sussman, Summer S. Han, John K. Ratliff, Stephen Skirboll, Austin Y. Feng, Caroline Berube, Michael C. Jin
Publikováno v:
Thrombosis Research. 204:126-133
Introduction Venous thromboembolism (VTE) management increasingly involves anticoagulation with direct oral anticoagulants (DOACs). Few studies have used competing-risks analyses to ascertain the mortality-adjusted hemorrhage and recurrent VTE (rVTE)
Publikováno v:
Thrombosis Research. 202:24-30
Introduction Following successful phase-III trials, direct oral anticoagulants such as rivaroxaban have largely replaced warfarin for stroke prevention in atrial fibrillation (SPAF). However, data from randomized trials should be confirmed in unselec
Autor:
Ane Abad-Motos, Juan Churruca, Beatriz Mestre-Gómez, Juan Torres-Macho, Juan A. Martín-Navarro, Cristina Cortina-Camarero, Rosa María Lorente-Ramos, Paz Arranz-García, Jacobo Rogado, Nuria Muñoz-Rivas, Pedro Torres-Rubio, Pablo Ryan, Eloy Gómez-Mariscal, Soledad R. Alonso-García, Eva Moya-Mateo, Cristina Mauleón-Fernández, Fernando Sierra-Hidalgo, Teresa Saez-Vaquero, Ana Isabel Franco-Moreno, Jose Angel Hernandez-Rivas, Ana Such-Diaz
Publikováno v:
Thrombosis Research
Background Incidence of thrombotic events associated to Coronavirus disease-2019 (COVID-19) is difficult to assess and reported rates differ significantly. Optimal thromboprophylaxis is unclear. Objectives We aimed to analyze the characteristics of p
Autor:
Mauricio Ferri, Huseyin Yuce, Cristina Russ, Robert D. McBane, Allison Keshishian, Jennifer D Guo, Tayla Poretta, Jack Mardekian, Lisa Rosenblatt, Patrick Hlavacek
Publikováno v:
Thrombosis Research. 198:163-170
Background The AMPLIFY trial found significantly lower major bleeding (MB) and similar recurrent venous thromboembolism (VTE) risks associated with apixaban vs warfarin among patients with VTE. Objectives To compare MB, clinically-relevant non-major
Autor:
Jackson King, Ashok Pai, Nathan P. Clark, Daniel M. Witt, Thomas Delate, Malti Charlu, Shiyun Zhu, Jordan B. King
Publikováno v:
Thrombosis Research. 196:367-370
Background First-line treatment and secondary prevention of venous thromboembolism (VTE) in patients with cancer consisted, historically, of unfractionated heparin or low-molecular weight heparin (LMWH). With recent clinical trials of direct oral ant
Autor:
Il Young Oh, Ju Hyeon Lee, Seong Soon Kwon, Sangyoung Kim, Yang Ki Kim, Hyeon Jong Yang, Ji Yun Lee, Soo Mee Bang
Publikováno v:
Thrombosis Research. 195:243-249
Introduction Direct oral anticoagulants (DOACs) have the potential to increase bleeding due to drug-drug interactions (DDIs). In the present study, the risk of bleeding was evaluated when drugs with potential DDIs were simultaneously prescribed with
Autor:
Steffany N Nguyen, Eric Salazar, Nicholas Jakowenko, Ashley Dinh, Kevin R. Donahue, Melanie C Ruegger
Publikováno v:
Thrombosis Research
Background Oral factor Xa inhibitors (FXaI) can be administered in fixed doses without the need for routine laboratory monitoring. Anti-Xa assays can estimate anticoagulant effect for specific FXaI's. The aim of this study was to characterize anti-Xa
Autor:
Julie Curtin, Yanyan Li, Faraizah Abdul Karim, Claude Negrier, Elena Santagostino, Wilfried Seifert
Publikováno v:
Thrombosis Research. 188:85-89
Introduction Long-acting recombinant factor IX (FIX) products may simplify the surgical treatment of haemophilia B patients. The impact of rIX-FP, a recombinant FIX fused to recombinant albumin, on FIX consumption and surgical management was assessed
Publikováno v:
Thrombosis Research. 185:63-71
Introduction Novel oral anticoagulants (NOACs) and warfarin care bundles (e.g. genotyping, patient self-testing or self-management) are alternatives to usual warfarin care for stroke prevention in patients with atrial fibrillation (AF). We aim to eva
Autor:
Valentin J. Krieg, Christian Troidl, Stefan Guth, Sebastian Kölmel, Mareike Lankeit, Lukas Hobohm, Stavros Konstantinides, Christoph Liebetrau, Eckhard Mayer, Christoph B. Wiedenroth
Publikováno v:
Thrombosis Research. 185:20-26
Introduction Although a number of risk factors for chronic thromboembolic pulmonary hypertension (CTEPH) have been reported, the exact prevalence is controversial and varies between published cohorts. The aim of the present study was to investigate t